Mergers and Acquisitions

The acquisition of Protein Sciences, a vaccines biotechnology company, strengthens Sanofi’s influenza vaccines portfolio.

The $12-million acquisition will strengthen Cancer Genetics Inc.’s (CGI) capabilities in drug discovery, drug development, and early phase clinical trial testing in the field of oncology.

The acquisition adds sterile manufacturing capability to the CDMO’s services, which include API formulation and manufacturing.

Upon merging, the combined company will be named SELLAS Life Science Group and will focus on cancer treatments with a late-stage pipeline featuring immunotherapies targeting hematology and solid tumors.

On August 3, 2017, Bristol-Myers Squibb (BMS) announced that it has agreed to acquire biotech firm, IFM Therapeutics, in a deal worth over $1 billion to develop BMS’ oncology pipeline.

Lonza further expands its micronization services with the acquisition of Swiss contract manufacturer, Micro-Macinazione, following its previous $5.5-billion acquisition of dosage form provider, Capsugel.

The Washington-headquartered biotech firm plans to use the newly purchased facility to produce antibodies for its current and future pipeline.

The acquisition will add recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio

Selexis will be integrated with KBI Biopharma, which was acquired by JSR Life Sciences in 2015.

The company said it expects to transaction to close on June 16, 2017.

Thermo Fisher will acquire Patheon for approximately $7.2 billion, including the assumption of approximately $2 billion of net debt.

Fresenius Kabi enters biosimilars market with acquisition of Merck KGaA’s Biosimilars Business

Sartorius acquired the Swedish company that specializes in data analytics software for biopharmaceutical development and manufacturing.

Permira will acquire LSNE, a CDMO for the pharmaceutical and medical device markets.

The companies will split Actellion’s drug discovery and early-stage clinical development assets into a new Swiss biopharmaceutical company.

WuXi AppTech acquired HD Biosciences, a preclinical drug-discovery-focused CRO.

The combined company’s turnover is estimated to reach €8 million ($8.35M) in 2017.

AGC adds second biopharma contract manufacturer with acquisition of CMC Biologics.

Baxter will acquire Claris Injectables Limited, adding additional generic injectable capabilities to the company’s porfolio.

Lonza adds CDMO, capsule, and consumer healthcare and nutrition capabilities with $5.5-billion acquisition of Capsugel.

Neovacs acquired Amegabiotech’s Interferon Alpha manufacturing license for the manufacture of its lead therapeutic candidate.

UPS entered into a definitive purchase agreement to acquire Marken, a provider of supply-chain solutions for the life-science industry.

Astellas will acquire Ganymed and its portfolio of ideal monoclonal antibody candidates.

Constantia Flexibles acquired a flexible packaging business from Lamp San Prospero SPA.

Pfizer announced its decision to remain one company after debating the possibility of splitting Pfizer Innovative Health and Pfizer Essential Health into two, separate publicly traded companies.